Researchers find model system to study promising cancer drug

Researchers have found that the budding yeast (Saccharomyces cerevisiae) is an acceptable model system to study KP1019, an anti-cancer drug that uses ruthenium, a rare metal, a new study found. Researchers had previously been interested in studying KP1019 because it is believed to cause cancer cell death and is not known to have negative secondary side effects for healthy tissues.

"We wanted to learn more about how KP1019 works on a cellular level, and how the drug acts on can be indicative of how it will perform on ," said Pamela Hanson, associate professor of biology at Birmingham-Southern College in Alabama. "Besides the economic advantages, there are good scientific reasons to work with yeast, including the abundance of yeast genetic and genomic tools."

In past research, KP1019 has been shown to inhibit ovarian tumor cell production, cause death of and reduce overall tumor size.

Along with testing the hypothesis that yeast could be a good model system for studying KP1019, researchers wanted to identify how the drug was internalized by cells. KP1019 was taken up within two hours and caused a dose-dependent increase in cell death. It was also found to delay within one hour, most likely the result of KP1019 binding to and damaging DNA.

"More research needs to be done on how KP1019 is internalized," said Hanson. "We suspect that the drug enters cells through more than one route."

Previous studies showed that this drug entered cancer cells, at least in part, through the transferrin-mediated iron-uptake pathway; however, yeast does not contain this specific pathway. Therefore, there must be other means for this drug to enter cells.

More information: The findings will appear in the January edition of the journal Molecular Pharmacology. KP1019 is currently in clinical trials.

add to favorites email to friend print save as pdf

Related Stories

Overcoming cancer drug resistance with nanoparticles

Jan 20, 2012

One of the ways in which cancer cells evade anticancer therapy is by producing a protein that pumps drugs out of the cell before these compounds can exert their cell-killing effects. A research team at Northwestern University ...

Recommended for you

Determine patient preferences by means of conjoint analysis

13 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments